Taxoter (docetaxel) and CPT 11 (irinotecan): The phase I trials;TAXOTERE (DOCETAXEL) ET CPT 11 (IRINOTECAN): LES PHASES I

Bulletin du Cancer

Volumn 83, Issue 1, 1996, Pages 3-10

  Couteau, C ^a   Yakendji, K ^a   Terret, C ^a   Goncalves, E ^a   Armand, J P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

CPT 11; phase I; Taxoter

Indexed keywords

DOCETAXEL; IRINOTECAN; ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; LOPERAMIDE; PACLITAXEL; TAXOID;

DIARRHEA; EDEMA; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; META ANALYSIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; REVIEW; SIDE EFFECT; WEIGHT GAIN; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG TOLERANCE; FEMALE; MALE; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ANTIDIARRHEALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; HUMANS; LOPERAMIDE; MALE; NEOPLASMS; NEUTROPENIA; PACLITAXEL; REMISSION INDUCTION; TAXOIDS;

EID: 0029717690     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Abigerges A, Armand JP, Chabot G et al. Irinotecan (CPT11) high dose escalation using intensive high dose loperamide to control diarrhea. J Natl Cancer Inst 1994;86:446-9
2. Bissery MC, Guenard D, Gueritte-Voegelein F. Experimental antitumor activity of Taxoter (RP 56976) a taxol analogue. Cancer Res 1994;51:4845-52
3. Bissery MC, Malhieu-Boué A, Lavelle F et al. Preclinical evaluation of intravenous CPT11, a soluble camptothecin derivative [Abstract]. Proc Am Assoc Cancer Res 1991;32:2380
4. Bissett D, Setanoians A, Cassidy J et al. Phase I and pharmacokinctic study of taxotcr (RP 56976) administered as a 24 hour infusion. Cancer Res 1993;53:523-7
5. Burris H, Irvin B, Kuhn J et al. Phase I clinical trial of Taxoter administered as either a 2 hour or 6 hour intravenous infusion. J Clin Oncol 1993;11:950-8
6. Clavel M, Mathieu-Boue A, Dumortier A et al. Phase 1 study of CPT11 administered as a daily infusion for 3 consecutive days [Abstract]. Proc Am Assoc Cancer Res. 1992;33:1568
7. D'Arpa P, Liu LF. Topoisomerase targetin antitumor drugs. Biochim Biophys Acta 1989;989:163-77
8. De Forni M, Bugat R, Chabot G et al. Study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994;54:4347-54
9. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxoter (RP 56976, NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53:1037-42
10. Frames Y, Gounon P, Bissery MC, Fellous A. Differential effects of Taxol® and Taxoter (RP 56976, NSC 628503) in Tau and MAP2 containing microtubules [Abstract]. Proc Am Assoc Cancer Res 1992;33:511
11. Gottlieb JA, Guarino A, Call JB, Oliveiro VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 1970;54:461-70
12. Hsiang YH, Herzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1987;260:14873-8
13. Jaxel C, Kohn KW, Weni RC, Wall ME, Pommier Y. Structure activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and relation to antitumor activity. Cancer Res 1989;49:1465-9
14. Kunimoto T, Nitta K, Tanako T et al. Antitumor activity of 7 ethyl 104(1 piperidino) 1 piperidino carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-7
15. Lavelle F, Fizaines C, Gueritte-Voegelein F, Guenard D, Potier P. Experimental properties of RP 56976, a Taxol® derivative [Abstract]. Proc Am Assoc Cancer Res 1989; 30:566
16. Matsuzaki T, Yokokuro T, Mutai M et al. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT 11 in mice. Cancer Chemother Pharmacol 1988;21:308-321
17. Mattis S, Aapro M, Zulian G et al. Phase 1 and pharmacokinetic study of RP 56976 in a new ethanol free formulation of Taxoter [Abstract]. Ann Oncol 1992;3(suppl 5): 28S
18. Muggia FM, Craven P, Hansen HH, Cohen MH. Phase I clinical trial of weekly and daily treatment with camplothecin sodium: correlation with preclinical studies. Cancer Chemother Rep 1972;56:515-21
19. Negoro S, Fukuoka M, Masuda N et al. Phase I study of weekly intravenous infusion of CPT 11, a new derivative of camptothecin, in the treatment of advanced non small cell lung cancer. J Natl Cancer Inst 1991;83:1164-8
20. Ohe Y, Saski Y, Shinkai T et al. Phase I study and pharmaokinetic of CPT 11 with 5 days infusion. J Natl Cancer Inst 1992;84:972-4
21. Pazdur B, Newman RA, Newman BM et al. Phase I trial of Taxoter: five days schedule. J Natl Cancer Inst 1992; 84:1781-8
22. Ringel I, Horowitz SB. Studies with RP 56976 (Taxoter): a semi synthetic analogue of Taxol®. J Natl Cancer Inst 1991;83:288-91
23. Riou JF, Naudin A, Lavelle F. Cellular activities of Taxoter [Abstract]. Proc Am Assoc Cancer Res 1992;33:525
24. Rothenberg ML, Kuhn JG, Burris HA et al. Phase 1 and pharmacokinetic trial of weekly CPT 11. J Clin Oncol 1993;11:2194-2204
25. Rowinsky EK, Grochow LB, Ettinger DS et al. Phase I and pharmacological study of the novel topoisomerase 1 inhibitor 7 ethyl 10 [4 (I piperidino) 1 peperidino] carbonyloxy-camptothecin (CPT 11) administered as a ninety minute infusion every 3 weeks. Cancer Res 1994;54:427-36
26. Suminaga M, Furue H, Taguchi T et al. Phase I study of CPT 11, a derivative of camptothecin [Abstract]. In: preceedings of the 16th International Congress on Chemotherapy, Jerusalem 1989
27. Tomiak E, Piccard MJ, Kerger J et al. Phase I study of docetaxel administered as a 1 hour infusion on a weekly basis. J Clin Oncol 1994;12:1458-67
28. Tzuruo T, Matsuzaki T, Matsushita M et al. Antitumor effect of CPT 11, a new derivative of camptothecin against pleiotropic drug resistant tumors in vitro et in vivo. Cancer Chemother Pharmacol 1988;21:71-4